Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

NCT05033847 is registered in ClinicalTrials.gov with National Vaccine and Serum Institute, China as lead sponsor.

NCT NCT05033847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05033847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
Lead sponsor
National Vaccine and Serum Institute, China
Phase
Phase 2
Overall status
Unknown status
Start date
September 12, 2021
Completion date
January 31, 2024
Enrollment
1,800 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infections, covid-19 pneumonia